The close interplay between thrombotic and immunologic processes plays an important physiological role in the immune defence after tissue injury and has the aim to reduce damage and to prevent the spread of invading pathogens. However, the uncontrolled or exaggerated activation of these processes can lead to pathological thromboinflammation. Thromboinflammation has been shown to worsen the outcome of cardiovascular, autoinflammatory, or even infectious diseases. Imaging of thromboinflammation is difficult because many clinically relevant imaging techniques can only visualize either inflammatory or thrombotic processes. One interesting option for the noninvasive imaging of thromboinflammation is multispectral 19F magnetic resonance imaging (MRI). Due to the large chemical shift range of the 19F atoms, it is possible to simultaneously visualize immune cells as well as thrombus components with specific 19F tracer that have individual spectral 19F signatures. Of note, the 19F signal can be easily quantified and a merging of the 19F datasets with the anatomical 1H MRI images enables precise anatomical localization. In this review, we briefly summarize the background of 19F MRI for inflammation imaging, active targeting approaches to visualize thrombi and specific immune cells, introduce studies about multispectral 19F MRI, and summarize one study that imaged thromboinflammation by multispectral 19F MRI.
Vascular inflammation plays a key role in the development of aortic diseases. A potential novel target for treatment might be CD73, an ecto-5′-nucleotidase that generates anti-inflammatory adenosine in the extracellular space. Here, we investigated whether a lack of CD73 results in enhanced aortic inflammation. To this end, angiotensin II was infused into wildtype and CD73−/− mice over 10 days. Before and after infusion, mice were analyzed using magnetic resonance imaging, ultrasound, flow cytometry, and histology. The impact of age and gender was investigated using female and male mice of three and six months of age, respectively. Angiotensin II infusion led to increased immune cell infiltration in both genotypes’ aortae, but depletion of CD73 had no impact on immune cell recruitment. These findings were not modified by age or sex. No substantial difference in morphological or functional characteristics could be detected between wildtype and CD73−/− mice. Interestingly, the expression of CD73 on neutrophils decreased significantly in wildtype mice during treatment. In summary, we have found no evidence that CD73 deficiency affects the onset of aortic inflammation. However, as CD73 expression decreased during disease induction, an increase in CD73 by pharmaceutical intervention might result in lower vascular inflammation and less vascular disease.
Fluorine-containing nanoparticles (FNPs) are widely used for inflammation imaging by fluorine-19 magnetic resonance imaging ( 19 F MRI) due to their biocompatibility and suitability to track immune cells via phagocytic uptake. For targeting approaches beyond passive incorporation, surface PEGylation of FNPs is required to reduce cellular uptake, but is known to prolong blood half-life of the particles. This study investigates the efficacy of FNP PEGylation for inflammation imaging in vivo. FNPs and PEGylated FNPs ( PEG FNPs) of different size were synthesized and characterized for particle properties and fluorine content. Cellular uptake was explored in CHO, RAW, and J774 cells as well as in whole blood using flow cytometry. For in vivo imaging, a murine lipopolysaccharide (LPS)-induced inflammation model was employed, followed by intravenous injection of FNPs or PEG FNPs and 19 F MRI to monitor inflammation. PEGylation significantly reduced the uptake of FNPs by macrophages and blood immune cells, as observed through reduced fluorescence and 19 F signals. Despite reduced cellular uptake in vitro, in vivo 19 F MRI showed similar signal intensities in inflamed tissues for both FNPs and PEG FNPs, suggesting contributions from both immune cell-associated and non-cell-associated signals for small particles. However, for bigger particles significantly more 19 F signal was observed in inflamed tissue for FNP compared to PEG FNP. In conclusion, increase in particle size can abolish the non-specific accumulation of FNPs in inflammatory lesions and additionally increase the phagocytosis of FNPs by murine immune cells. This results in a specific immune-cell dependent 19 F signal with rather no background due to non-specific diffusion.
Imaging and tracing materials inside the body is essential to develop functional materials for personalized therapies, including drug delivering nanocarriers and artificial tissues. Magnetic Resonance Imaging (MRI) is a key whole-body imaging technology, where heteronuclear MRI agents enable background-free, quantitative labeling. However, many MRI agents raised concerns due to environmental pollution and organ accumulation. As a solution, we developed a biodegradable, biocompatible polymer platform for heteronuclear 31P magnetic resonance imaging (MRI). We introduce polyphosphoester colloids for heteronuclear MRI using 31P-nucleus. 31P MRI has been severely hampered by unfavorable magnetic resonance properties of 31P, including intrinsic background and low sensitivity. We overcame these fundamental challenges in imaging of 31P by tailoring molecular and structural features of polymeric colloids. We have synthesized gradient-type polyphosphonate copolymers that self-assemble into well-defined micelles. The gradient leads to favorable MRI characteristics compared with homo- and block copolymers. Background-free imaging and biodegradation were proven in vivo in Manduca sexta. Furthermore, we demonstrate by encapsulation of the potent drug PROTAC ARV-825 that these amphiphilic copolymers can simultaneously deliver hydrophobic drugs and thus enable theranostics. We present a unique platform of biocompatible, degradable polyphosphoesters that inherently act as background-free MRI agents and delivery vehicles.